



Expanding Horizons in Lung Cancer Treatment: New Data and Emerging Biomarkers

Sunday, 21 October 2018 | 18:30–20:00
ICM–Room 13
Messe Munich
Munich, Germany

Program Topics



Meeting Chair

Clinical Considerations in NSCLC: Immunotherapy, Chemotherapy, or Both
&
Real-World Experience: Practical Management of Adverse Events With I-O
Martin Reck, MD, PhD
*LungenClinic Grosshansdorf
Grosshansdorf, Germany*



Developments in I-O Therapies for SCLC and Mesothelioma
Leora Horn, MD
*Vanderbilt-Ingram Cancer Center
Nashville, TN, United States*



Emerging Data on Potential Biomarkers in Lung Cancer Research
Jürgen Wolf, MD, PhD
*University Hospital of Cologne
Cologne, Germany*

Audience Q&A to Follow Presentations

This Industry-Sponsored Symposium Is Organized and Funded by Bristol-Myers Squibb.